Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is thought to be increased site-specific thrombin generation by tissue factor—mediated activation of coagulation or from activated platelets. However, there have also been many reports of thrombotic complications after recombinant factor VIIa administration. Randomized clinical trials and further laboratory studies should help better clarify the efficacy, safety, cost-effectiveness, and optimal dosing of recombinant factor VIIa in the cardiac surgical setting.
Ferraris VA, Ferraris SPLimiting excessive postoperative blood transfusion after cardiac procedures . A review. Tex Heart Inst J. 1995;22:216-230.
2.
Spahn DREliminating blood transfusions: new aspects and perspectives. Anesthesiology. 2000;93:242-255.
3.
Dacey LJ, Munoz JJ, Baribeau YR, et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Arch Surg. 1998;133:442-447.
4.
Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E., Lappas DGFactors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients . Anesth Analg. 1996;82:13-21.
5.
Food and Drug Administration.Novoseven coagulation factor VIIa (recombinant). FDA Web site. 2003.
6.
Hedner U.Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol.2001;38(4)(suppl 12): 43-47.
7.
Kjalke M., Ezban M., Monroe DM, Hoffman M., Roberts HR, Hedner U.High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001;114:114-120.
8.
Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638-648.
9.
Hedner U.Dosing with recombinant factor VIIa based on current evidence. Semin Hematol.2004;41(suppl 1): 35-39.
10.
Hedner U., Glazer S., Pingel K., et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193.
11.
Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GMSuccessful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth. 2003 ;50:599-502.
12.
Stratmann G., Russell IA, Merrick SHUse of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg. 2003;76:2094-2097.
13.
Tanaka KA, Waly AA, Cooper WA, Levy JHTreatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology . 2003;98:1513-1515.
14.
von Heymann C., Hotz H., Konertz W., Kox WJ, Spies C.Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery . J Cardiothorac Vasc Anesth. 2002;16:615-616.
15.
Raivio P., Suojaranta-Ylinen R., Kuitunen, AHRecombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80:66-71.
16.
Karkouti K. , Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26-34.
17.
Diprose P., Herbertson MJ, O'Shaughnessy D., Gill RSActivated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth.2005;95: 596-602.
18.
Bishop CV, Renwick WE, Hogan C., Haeusler M., Tuckfield A., Tatoulis J.Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006;81:875-879.
19.
von Heymann C., Redlich U., Jain U., et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med. 2005;33:2241-2246.
20.
Gowers CJRecombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care . 2005;33: 196-200.
21.
STS Blood Conservation Guideline Task Force , Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline . Ann Thorac Surg.2007;83(suppl 5):S27-86.
22.
Karkouti K. , Beattie WS, Crowther MA, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference . Can J Anaesth.2007;54:573-582.
23.
Erhardtsen E., Nony P., Dechavanne M., Ffrench P., Boissel JP, Hedner U.The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0.Blood Coagul Fibrinolysis. 1998;9:741-748.
Roberts HR: Safety profile of recombinant factor VIIa. Semin Hematol.2004;41(suppl 1):101-108.
26.
Brown JL, Varma S., Morgan-Hughes NJ, Rocco G.Thrombosis related to emergency factor VIIa treatment. Anaesthesia . 2003;58:1245.
27.
O'Connell NM , Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OPRecombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 2003;43:1711-1716.
28.
Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg . 2007;84:161-168.
29.
Mayer SA, Brun NC, Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage . N Engl J Med. 2005;352:777-785.
30.
Thomas GO, Dutton RP, Hemlock B., et al. Thromboembolic complications associated with factor VIIa administration . J Trauma. 2007;62:564-569.
31.
Food and Drug Administration.http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#NovoSeven .
32.
O'Connell KA , Wood JJ, Wise RP, Lozier JN, Braun MMThromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
33.
Mazer D., Leong-Poi H., Latter D., Strauss B., Teitel J.Effect of recombinant factor VIIa on vascular graft patency [abstract A852] . Anesthesiology. 2007;107.
34.
Charbonneau S., Girard F., Boudreault D., Ruel M., Blais N., Hardy JFRecombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding. Thromb Haemost. 2007;97:296-303.
